Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial

Purpose Physicians sometimes make management recommendations on the basis of early results from randomized controlled trials (RCTs) relating to reduced prostate-specific antigen (PSA) failure, yet whether this early end point is associated with all-cause mortality (ACM), particularly in men with com...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2016-11, Vol.34 (31), p.3781-3786
Hauptverfasser:	Giacalone, Nicholas J, Wu, Jing, Chen, Ming-Hui, Renshaw, Andrew, Loffredo, Marian, Kantoff, Philip W, D'Amico, Anthony V
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Androgen Antagonists - therapeutic use Brachytherapy - methods Cause of Death Chemoradiotherapy Comorbidity Humans Male ORIGINAL REPORTS Outcome Assessment (Health Care) - methods Outcome Assessment (Health Care) - statistics & numerical data Proportional Hazards Models Prostate-Specific Antigen - analysis Prostatic Neoplasms - metabolism Prostatic Neoplasms - mortality Prostatic Neoplasms - therapy Randomized Controlled Trials as Topic Risk Factors Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!